Gastric Cancer News and Research

RSS

Hutchison MediPharma achieves primary endpoint in POC Phase II study to treat NSCLC patients

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, successfully achieved the primary endpoint in the second proof-of-concept ("POC") trial of fruquintinib in patients with advanced non-squamous non-small cell lung cancer ("NSCLC") in China.

4 Sep 2015

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

Bile duct cancer is rare and is usually detected too late. Often only extensive liver surgery can help or, in rare cases, liver transplantation. But which patients will benefit from surgery and which will not, because their risk of cancer recurrence is too high? With the oncogene MACC1 as a biomarker, physicians for the first time have a tool to decide which treatment option is best for patients with Klatskin carcinoma, one type of bile duct cancer.

1 Sep 2015

LINE-1 jumping gene unusually active in gastrointestinal cancer

Results of a trio of studies done on human cancer tissue biopsies have added to growing evidence that a so-called jumping gene called LINE-1 is active during the development of many gastrointestinal cancers.

19 Aug 2015

Studies show jumping genes more active during development of gastrointestinal cancers

18 Aug 2015

Study reveals that miR-7 suppresses gastric cancer by inhibiting key signaling pathway

A study in The Journal of Cell Biology reveals that the microRNA miR-7 suppresses gastric (stomach) cancer by inhibiting a key signaling pathway, and that this protective mechanism is compromised by the cancer-causing bacterium H. pylori. Finding drugs capable of inducing miR-7 could therefore prove to be an effective treatment against the progression of gastric cancer.

11 Aug 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced a collaboration with Galectin Therapeutics to use the BreathID test to monitor patients in a Phase II study evaluating GR-MD-02.

3 Aug 2015

Eradicating H. pylori bacterium with short course of therapy may help prevent gastric cancer

A new review published in the Cochrane Library, indicates that eradicating Helicobacter pylori bacterium-- the main cause of stomach ulcers - with a short course of therapy comprising two commonly used medicines may help to reduce the risk of gastric cancer. Stomach, or gastric, cancer is the third most common cause of death from cancer worldwide, and people who are infected with the Helicobacter pylori bacterium are more likely to develop the disease.

23 Jul 2015

Researchers identify five recurrent fusion genes involved in acute gastritis and cancer

Studying the gastric cancers of 15 Southeast Asian patients, researchers at The Jackson Laboratory, the Genome Institute of Singapore and other institutions identified five recurrent fusion genes, one of which appears to lead to cellular changes involved in acute gastritis and cancer.

10 Jul 2015

Larrea Biosciences merged into Gordian Holdings

Larrea Biosciences has been merged into Gordian Holdings, Inc. "Marshalling the Body's best Offense and Defense against Disease, Its own Immune System, through Immunotherapy." Gordian Holdings obtained the rights from OnkologixRx, Inc., for the Markets in China and North America.

25 Jun 2015

AGA Research Foundation raises $10.5 million to support GI research

The American Gastroenterological Association is pleased to announce that the AGA Research Foundation has raised more than $10.5 million to support digestive disease and hepatology research through the Looking Forward: Giving Back endowment campaign.

24 Jun 2015

New breath test could help diagnose oesophageal and gastric cancer in minutes

Researchers have devised a breath test that can help doctors diagnose the early signs of oesophageal and gastric cancer in minutes.

23 Jun 2015

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant.

19 Jun 2015

Researchers reveal that Helicobacter pylori infection can lead to gastric cancer

Around half of the global population is chronically infected with the stomach bacterium Helicobacter pylori, almost 1 percent of whom go on to develop gastric adenocarcinoma, one of the deadliest forms of cancer. Usually it takes many decades for the cancer to develop, making it difficult to pinpoint exactly how it is linked to an infection.

17 Jun 2015

Scientists develop new technique to analyze bacterial populations

Scientists from the Icahn School of Medicine at Mount Sinai have developed a new technique to more precisely analyze bacterial populations, to reveal epigenetic mechanisms that can drive virulence. The new methods hold the promise of a potent new tool to offset the growing challenge of antibiotic resistance by bacterial pathogens.

16 Jun 2015

Certain ARID1a mutations sensitize some tumors to PARP inhibitor drugs

Mutations in ARID1a, which are common in many cancer types, disrupt DNA damage repair in cancer cells, allowing the cancer to progress. This gene may also be an Achilles' heel when treating certain tumors, according to a team of researchers at The University of Texas MD Anderson Cancer Center.

12 Jun 2015

Exalenz Bioscience initiates BreathID clinical study to detect primary liver cancer

Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced the initiation of a clinical study designed to investigate its BreathID test to non-invasively detect primary liver cancer, also known as Hepatocellular Carcinoma (HCC).

4 Jun 2015

Ariana Pharma joins the GastricGlycoExplorer consortium

This collaboration is carried out within the GastricGlycoExplorer consortium, a European Commission funded project. The consortium aims at discovering and developing new diagnostic signatures by characterizing the sugars that are attached to the surface of gastric tissue. "Glycomics" provides a systematic approach for studying sugars that are naturally present on cell surfaces and its application may lead to determine early markers of gastric cancer.

2 Jun 2015

FDA clears ADXS-HPV plus epacadostat IND for HPV-associated cervical cancer Phase 2 study

Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, today announced the clearance of the Investigational New Drug application by the United States Food and Drug Administration to conduct a Phase 2 study of ADXS-HPV (ADXS11-001) alone or in combination with Incyte Corporation's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360), for the treatment of Stage I-IIIb human papillomavirus (HPV)-associated cervical cancer.

1 Jun 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.